Screener
Ardent Health Partners ARDT Income Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| $1.62B+3.1% | $1.62B-1.4% | $1.6B+7.0% | $1.61B-0.1% | $1.58B+8.8% | ||
| $41.06M+4.9% | $41.34M+5.2% | $42.99M+18.7% | $41.04M+8.4% | $39.16M+6.5% | ||
| $1.58B+3.0% | $1.58B-1.6% | $1.56B+6.7% | $1.56B-0.3% | $1.54B+8.8% | ||
| 97.5%0.0pp | 97.5%-0.2pp | 97.3%-0.3pp | 97.4%-0.2pp | 97.5%+0.1pp | ||
| —— | $61.2M+87.7% | $48.6M+39.3% | $36.8M+0.3% | $36.5M+8.3% | ||
| $1.54B-2.2% | $1.58B+3.7% | $1.53B+7.3% | $1.51B+5.1% | $1.58B+13.4% | ||
| $15.32M+10.1% | $12.57M-14.7% | $12.21M-13.9% | $12.38M-8.5% | $13.91M-4.9% | ||
| —— | $1.73M+495% | -$1.01M+4.4% | -$3.4M-165% | -$330K— | ||
| $81.03M+3,778% | $43.2M-64.6% | $74.59M+0.5% | $92.37M-44.8% | -$2.2M-104% | ||
| $17.64M+617% | $8.51M-67.6% | $16.1M+5.7% | $18.11M-31.3% | -$3.41M-131% | ||
| $44.52M+290% | $16.9M-76.8% | $39.85M-3.7% | $44.96M-60.6% | -$23.48M-189% | ||
| 2.7%+4.2pp | 1%-3.4pp | 2.5%-0.3pp | 2.8%-4.3pp | -1.5%-3.3pp | ||
| $0.31+282% | $0.12-76.9% | $0.28-3.4% | $0.32-61.9% | -$0.17-189% | ||
| $137.4M+170% | $97.11M-44.8% | $129.79M+4.2% | $145.79M-33.3% | $50.87M-53.1% | ||
| 8.5%+5.2pp | 6%-4.7pp | 8.1%-0.2pp | 9.1%-4.5pp | 3.2%-4.3pp | ||
| $96.34M+723% | $55.77M-59.2% | $86.8M-1.8% | $104.75M-42.1% | $11.71M-83.7% |
FAQ
- What is Ardent Health Partners's revenue?
- Ardent Health Partners (ARDT) generated $6.5B in revenue over the trailing twelve months, up 2.0% year over year.
- Is Ardent Health Partners profitable?
- Ardent Health Partners reported $146.2M in net income over the trailing twelve months, a 2.3% net margin.
- What is Ardent Health Partners's earnings per share?
- Ardent Health Partners's diluted EPS over the trailing twelve months is $1.03.
- Where does Ardent Health Partners's income statement data come from?
- Every line is extracted from Ardent Health Partners's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
